Skip to main content
. 2022 Jan 17;207(3):307–317. doi: 10.1093/cei/uxac006

Figure 5:

Figure 5:

PD-L1+ EVs can be used as a marker of progression-free survival in SCLC. Kaplan–Meier estimates of progression-free survival (PFS) in patients according to total PD-L1 (n = 70, P = 0.063) (A) or exosomal PD-L1 (n = 70, P = 0.0002) (B). HR, hazard ratio; CI, confidence interval.